BMS’ Opdivo plus Yervoy combo gets EC approval for metastatic NSCLC
Bristol Myers Squibb (BMS) has secured approval from the European Commission (EC) for Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of metastatic non-small ... Read More
Covid-19 phase 3 trial of lenzilumab : Humanigen announces positive interim results
Humanigen said that lenzilumab has delivered a clinically meaningful impact on the recovery of patients hospitalized with Covid-19, as per the interim data of a ... Read More
AstraZeneca gets BRILINTA FDA approval for reducing risk of stroke in acute ischemic stroke or high-risk transient ischemic attack
BRILINTA FDA approval : AstraZeneca has bagged approval for BRILINTA (ticagrelor) from the US Food and Drug Administration for its use in reducing the risk ... Read More
Seres Therapeutics begins phase 1b trial of SER-301 in ulcerative colitis
Seres Therapeutics has dosed the first patient in a phase 1b clinical trial, which is assessing SER-301 for the treatment of active mild-to-moderate ulcerative colitis ... Read More
Novo Nordisk to acquire US drug delivery company Emisphere Technologies
Danish pharma company Novo Nordisk has agreed to acquire US drug delivery company Emisphere Technologies in a deal worth $1.8 billion. The proprietary drug delivery ... Read More
PerkinElmer to acquire cell engineering company Horizon Discovery
US-based PerkinElmer will acquire UK-based cell engineering company Horizon Discovery Group for nearly $383 million in an all-cash deal. The transaction, which is subject to ... Read More
FTC gives conditional approval to Mylan’s acquisition of Upjohn from Pfizer
The US Federal Trade Commission (FTC) has granted conditional approval for Dutch pharma company Mylan’s acquisition of Upjohn, the off-patent branded and generic established medicines ... Read More
Novartis acquires optogenetics gene therapy company Vedere Bio
Novartis acquisition of Vedere Bio : US-based stealth-stage company Vedere Bio has been acquired by Swiss pharma giant Novartis in a deal worth up to ... Read More
Lilly signs $375m deal to supply Covid-19 candidate bamlanivimab to US govt
Eli Lilly and Company (Lilly) has signed a $375 million deal with the US government for the supply of 300,000 vials of bamlanivimab (LY-CoV555) 700mg, ... Read More
Exact Sciences to acquire Thrive Earlier Detection for $2.15bn
Exact Sciences, a US molecular diagnostics company, has agreed to acquire Thrive Earlier Detection in a cash cum stock deal worth up to $2.15 billion, ... Read More